The binding of tissue-type plasminogen activator (t-PA) to membranes prepared from human liver was investigated, and a specific, saturable, high-affinity binding site (Kd = 3.4 nM) was identified. The binding of t-PA to liver membranes was not affected by an excess of D-mannose or D-galactose, or by active urokinase (u-PA), whereas binding of t-PA to membranes prepared from human HepG2 hepatoma cells was inhibited by u-PA. HepG2-membrane-bound t-PA was fully complexed to PA inhibitor 1 (PAI-1), whereas liver-membrane-bound t-PA was not complexed. Gel filtration on Sephacryl S300 of membrane proteins solubilized in deoxycholate revealed that high-affinity t-PA binding activity elutes at an apparent molecular mass of 40 kDa. Monoclonal antibodies specific for the growth factor and the kringle 2 domains inhibited the binding of t-PA to liver membranes and the catabolism of t-PA by rat hepatoma cells. Human liver membranes also bound u-PA; binding was inhibited by pro-u-PA, the N-terminal fragment of u-PA, but not by the 33 kDa form of u-PA or by t-PA. Our results show that human liver membranes contain a specific 40 kDa binding protein for t-PA that is different from the PAI-1-dependent receptor described on HepG2 cells and the mannose receptor isolated from human liver.
INTRODUCTION
Tissue-type plasminogen activator (t-PA), a serine proteinase that plays a key role in the prevention of thrombosis and which is used as a thrombolytic agent, is rapidly cleared by the liver. In rats, t-PA is cleared mainly via a mannose receptor on liver endothelial cells and Kupffer cells (Einarsson et al., 1988; Kuiper et al., 1988; Smedsr0d & Einarsson, 1990; Seydel et al., 1991; Otter et al., 1991) and a specific receptor on parenchymal cells. t-PA mutants lacking one or more of the sugar residues, or t-PA from which the carbohydrates have been removed by endo-Nacetyglucosaminidase treatment, are cleared more slowly (Hotchkiss et al., 1988; Tanswell et al., 1989; Einarsson et al., 1989) , in accordance with a role for the mannose receptor (Otter et al., 1991) . The mechanism of clearance via parenchymal cells is still a matter of controversy. Some studies propose an essential role for plasminogen activator inhibitor type 1 (PAI-1), whereas other studies propose a mechanism independent of PAI-1. In human HepG2 hepatoma cells t-PA first binds to PAI-1; thereafter, the complex binds to the cells, and is internalized and degraded (Owensby et al., 1989; Morton et al., 1990) . Results obtained with a suspension of human hepatocytes, obtained after collagenase dispersion, were in accordance with the findings with HepG2 cells (Wing et al., 1991a) . Furthermore, in an isolated perfused rat liver system, t-PA-PAI-1 complexes were cleared more rapidly than t-PA alone (Wing et al., 1991b) . Several observations, however, argue against clearance solely via PAI-1-dependent mechanisms: (1) the clearance rates of active-siteblocked t-PA or of an inactive t-PA mutant are identical to that of active t-PA (Fuchs et al., 1985; Ord et al., 1990) and the clearance of radioactive t-PA is not influenced by a 10000-fold excess of u-PA (Fuchs et al., 1985; Krause et al., 1990) ; (2) almost all domain deletions from the heavy chain of t-PA result in a prolongation of the clearance of t-PA, whereas the proteinase domain is the primary domain interacting with PAI-I (reviewed in Krause, 1988) ; and (3) in rat primary hepatocytes (Krause et al., 1990) and in rat Novikoff hepatoma cells (Nguyen et al., 1992 ) the binding of t-PA is followed by internalization and degradation, and cannot be blocked by an excess of u-PA.
Purification and characterization of the receptor(s) mediating the internalization and degradation of t-PA will be essential to establish the relative importance of the different mechanisms involved in the clearance of t-PA in vivo. To investigate whether human liver would be a suitable source for the purification of the t-PA receptor, we characterized the binding of t-PA to plasma membranes prepared from human liver. Our findings show that human liver membranes contain a distinct high-affinity binding site for t-PA that is not dependent on PAI-I and is different from the urokinase (u-PA)-binding site. Analysis by gel filtration suggests that the t-PA-binding protein has a size of approx. 40 kDa.
EXPERIMENTAL Materials
Melanoma t-PA, 98 % single chain, was purchased from Biopool (Umei, Sweden). Active u-PA was a gift from Serono (Coinsins, Switzerland). The 33 kDa low-molecular-mass form of u-PA was from Mochida; non-glycosylated pro-u-PA, produced in Escherichia coli, was from Grunenthal (Aachen, Germany); and the N-terminal fragment of u-PA was a gift from Dr. J. Krause (Dr. Karl Thomae GmbH, Biberach an der Riss, Germany). Sodium deoxycholate was purchased from Fluka, -and Sephacryl S300 was from Pharmacia (Uppsala, Sweden). Triton X-1 14 was obtained from Sigma, and Na125I was from New England Nuclear. The proteinase inhibitors aprotinin (Trasylol) and phenylmethanesulphonyl fluoride (PMSF) were from Bayer and Sigma respectively. Monoclonal antibodies (mAbs) to t-PA were obtained as previously described 
Labelling of plasminogen activators
The proteins were iodinated using the lodogen method (Fraker & Speck, 1978) to specific radioactivities of 1 ,uCi/pmol for 1251-t-PA and 0.5 ,uCi/pmol for l25l-pro-u-PA.
Preparation of plasma membranes
Human liver was obtained during partial hepatectomy from a patient with a hepatocarcinoma. Non-cancerous tissue was macroscopically isolated, immediately cooled and washed extensively in cold 150 mM-NaCl before storing at -70 'C. The tissue (150 g) was finely chopped in 1500 ml of homogenization buffer (5 mM-Tris/HCl, pH 7.4, containing 0.25 M-sucrose, 1 mM-EGTA, 500 units of Trasylol/ml and 1 mM-PMSF) and homogenized at 0 'C in a 50 ml Potter-Elvehjem Homogenizer with a Teflon pestle. HepG2 cells (10 x 106 cells/ml) were washed in cold Krebs-Henseleit buffer (118 mM-NaCl, 5 mM-KCl, 1.1 mM-MgSO4, 2.5 mM-CaCl2, 1.2 mM-KH2PO4, 25 mMNaHCO3, pH 7.4), resuspended in homogenization buffer and homogenized. Enriched outer membranes were obtained according to the method of Hwang (1987) . Briefly, following homogenization, 15 ml of the liver or HepG2 cell homogenate was loaded on to 10 ml of 1.45 M-sucrose in 20 mM-Tris/HCl, pH 7.4, and centrifuged at 35000 g (25000 rev./min) for 30 min in a Beckman SW 28 rotor. The membranes at the interface were collected, pelleted for 20 min at 40000 g (35000 rev./min) in a Beckman 70 Ti rotor, and washed three times in 10 mM-Hepes, pH 7.4, containing 0.25 M-sucrose, 5 mM-MgCl2, 0.2 mM-CaCl2, 250 units of Trasylol/ml and 0.5 mM-PMSF, reconstituted in the same buffer to a protein concentration of 5 mg/ml, and frozen at -70 'C. The protein content was determined by the method of Peterson (1977) . The plasma membrane specific marker enzymes alkaline phosphatase and 5'-nucleotidase, and acid phosphatase, a lysosomal marker, were measured using routine clinical chemistry procedures. A quantitative analysis of enzyme activities and protein concentrations revealed that the membrane preparation procedure used resulted in an I 1.1-fold enrichment of the plasma membrane markers with respect to total proteins, and a 4.4-fold enrichment with respect to the lysosomal membrane marker.
Binding to intact membranes
Membranes from human liver or HepG2 cells were washed and diluted to 1 mg/ml in Krebs buffer containing 1 % BSA (Krebs/BSA) and tested for 125I-PA binding. A 10 1ul portion of membranes was incubated in Eppendorf tubes with 10 #1 of Krebs/BSA containing 300 pM-'251-t-PA or 500 pM-1251-u-PA plus 0l
O . of buffer containing unlabelled t-PA or u-PA (0-1000 nM), or 50 mM-mannose or -galactose for 15 min at 37 'C. Membranes were then microcentrifuged with 10 min at 10000 rev./min and washed with 1 ml of cold Krebs buffer, and membrane-associated radioactivity was counted.
Analysis of complex formation of human t-PA with inhibitor Radiolabelled t-PA (10 fmol; 10000 c.p.m.) was incubated for 30 min at 37 'C with 50 ,1 (100 ,ug) of human liver or HepG2 membrane proteins. The membranes were isolated by centrifugation, and the reaction was stopped and membrane proteins solubilized by the addition of SDS/PAGE sample buffer. Proteins were separated by SDS/PAGE on a 7.5 % gel (Laemmli, 1970) and, after drying, the gels analysed by autoradiography.
Solubilization of human liver membranes Liver membranes were washed and reconstituted at 5 mg/ml in Krebs buffer and solubilized by addition of an equal volume of 2 % deoxycholate in 0.5 M-KHCO3/0.25 M-NaCl, pH 8.2, and mixing for 2 h at 4 'C. Insoluble proteins were removed by centrifugation (100000 g, 4 'C, 30 min).
Assay for t-PA binding activity in solubilized membrane proteins Samples of 10 ,d of solubilized membrane proteins, diluted in Krebs/BSA to 0.5 mg/ml, or of gel filtration fractions (see below) were incubated for 30 min at 37 OC with 10 IlI of 1251-t-PA (10000 c.p.m.) and 10 ,ul of buffer with or without competitor. Cold 0.1 % Triton X-1 14 (1 ml) containing 1 ,tg of Bromophenol Blue/ml was added and the tubes were warmed at 37 'C for 2 min to induce Triton X-l 14-phase separation (Bordier, 1981) .
After centrifugation for 1 min at 10000 rev./min in a microcentrifuge, labelled ligand bound to integral membrane proteins was recovered in the lower (blue-coloured) detergentrich phase, whereas unbound ligand remained in the supernatant. The detergent-rich phase was washed with 1 ml of cold Krebs buffer before counting the associated radioactivity.
Gel filtration analysis
A Sephacryl S300 column (2 cm x 90 cm) was equilibrated at 4°C using 10 mM-Tris/HCl, 150 mM-NaCl and 0.05 % sodium deoxycholate, pH 8.3. Solubilized membranes containing 10 mg of protein in 2.5 ml were loaded on the column and eluted at a flow rate of 20 ml/h. The column was calibrated using molecular mass marker proteins (Serva, Heidelberg, Germany): equine myoglobin (17 kDa), BSA (67 kDa), aldolase (160 kDa) and ferritin (450 kDa). Fractions of 1 ml were collected; their protein content was measured (Peterson, 1977) and they were assayed for t-PA binding activity using Triton X-1 14 as described above.
Effect of mAbs on binding of t-PA
In preliminary studies, 100 ,u of labelled t-PA in Krebs buffer was incubated for 2 h at 37 'C with 100 ,1 ofmAb (0.1-50 ,tg/ml), and complexes were immunoprecipitated by addition of 100 ,ul of a suspension of cellulose coated with donkey anti-mouse antibodies (Sac Cel; Wellcome, Beckenham, Kent, U.K.; used undiluted). The precipitated complexes were washed three times with 2 ml of 50 mM-Tris/HCl, pH 7.4, containing 0.001 % Tween 80, and the radioactivity was counted. All mAbs tested showed half-maximal binding at concentrations below 1 jtg/ml. As a result, the effects of the mAbs on t-PA binding to liver membranes were tested at concentrations between 5 and 50 ,ug/ml.
To study the effect of a particular mAb on the binding of 1251_
t-PA to liver membranes, labelled t-PA was incubated for 2 h at 37 "C with mAb at a concentration at least 10 times that giving half-maximal binding ,ig/ml). The amount of 1251-t-PA bound to membrane proteins was determined by counting.
Effect of mAbs on the catabolism of t-PA by rat hepatoma cells Radiolabelled t-PA was preincubated with buffer containing unlabelled t-PA (1 suM) or mAbs at concentrations of 20 ,tg/ml (which is at least 10 times that giving half-maximal binding to t-PA; see above) for 2 h at 37°C, and then added (1:2, v/v) to Novikoff cells (5 x 106 cells/ml). At timed intervals 106 cells were withdrawn, separated from the supernatant by centrifugation for 1 min at 1000 g in a microcentrifuge and washed with 1 ml of cold Krebs buffer. The supernatant was incubated with trichloroacetic acid (final concentration 10 %) for 30 min at 4°C and precipitated proteins were collected by microcentrifugation (10 min, 10000 rev./min). The amounts of radioactivity associated with the cells, precipitated by trichloroacetic acid and soluble following trichloroacetic acid treatment were determined in a y-radiation counter.
of radiolabelled t-PA to proteins in the 40 kDa fraction was analysed. Unlabelled t-PA reduced the binding of radiolabelled t-PA from 19.3 % to 7.4 %, whereas u-PA had no effect.
Effects of mAbs on the binding of t-PA to liver membranes
To identify the domain of t-PA interacting with the liver membranes, we used a panel of mAbs specific for the different domains of t-PA. All mAbs specific for the epidermal growth factor (EGF)-like domain and the kringle 2 domain were found to strongly inhibit t-PA binding, whereas an mAb specific for the kringle 1 domain (PAM 1) had a lesser inhibitory effect, and the mAbs specific for the finger (AD# 370) and proteinase (PAM-1) domains had no effect (Table 1) The presence of specific t-PA-binding proteins on human liver membranes was investigated by incubating 10 ,1 of membranes (1 mg of protein/ml) with 10000 c.p.m. of radiolabelled t-PA in the absence or presence of 330 nm unlabelled t-PA, u-PA or prou-PA. Excess unlabelled t-PA decreased membrane-associated radioactivity by 63 %, whereas active u-PA or pro u-PA had no effect. In contrast, the binding of t-PA to HepG2 membranes were decreased both by unlabelled t-PA (from 17.0% to 7.1 %) and by u-PA (to 10.0%), but not by pro-u-PA. Analysis by SDS/PAGE of membrane-bound radiolabelled t-PA revealed that t-PA bound to HepG2 membranes had formed a 110 kDa complex, which has previously been shown to be t-PA-PAI-1 (Morton et al., 1990) , whereas t-PA bound to liver membranes had not formed such a complex (Fig. 1) .
The effect of sugars on the binding of t-PA to liver membranes was investigated. In the presence of 50 mM-mannose or -galactose, the binding of t-PA to the liver membranes was 8.3 +0.7% and 8.6+0.6 % (mean+s.D., n = 4), respectively whereas in the absence of these sugars binding was 8.7 + 0.2 %.
Characteristics of '251-t-PA binding to human liver membranes
The binding of radiolabelled t-PA to intact human liver membranes was saturable. Scatchard analysis of binding to human liver membranes at 200 ,ug/ml (Fig. 2) (Fig. 3) . Fig. 3 . Gel filtration analysis of t-PA binding proteins in solubilized human liver membranes Solubilized human liver membranes (10 mg in 2.5 ml) were loaded on to a Sephacryl S300 column (2 cm x 90 cm) pre-equilibrated with 1O mM-Tris/HCl, 150 mM-NaCl and 0.050/ sodium deoxycholate, pH 8.3 . The eluted fractions were tested for t-PA binding activity using a Triton X-1 14 phase separation assay. The elution volumes of equine myoglobin (17.8 kDa), BSA (67 kDa), aldolase (160 kDa) and ferritin (450 kDa) are indicated above the chromatogram. (Fig. 4) .
In the presence of 1 UM unlabelled t-PA the appearance of degradation products was completely blocked. Co-incubation with 10 ,ug of mAb A0 or mAb BI 1/ml, or of the two combined, resulted in almost complete inhibition of the appearance of degradation products. u-PA at a concentration of 100 nm had no effect (results not shown).
Characteristics of u-PA binding to human liver membranes As pro-u-PA is also rapidly cleared via the liver, we studied the binding of pro-u-PA to liver membranes. Binding of '25I-pro-u- PA to liver membranes was saturable and inhibited by an excess of unlabelled u-PA, pro-u-PA and the N-terminal fragment of u-PA, but only slightly by an excess of unlabelled low-molecularmass u-PA (Fig. 5) , and not at all by t-PA (results not shown). These results show that the pro-u-PA-binding protein on human liver membranes is different from that binding t-PA, and binding is mediated via the light chain of u-PA.
DISCUSSION
The concentration of active t-PA in plasma is regulated at three different levels: the release of t-PA from the vascular endothelium, the inactivation by PAI-1, and the rapid clearance of PAs via the liver. The present study was undertaken to
Plasminogen activator binding to human liver membranes characterize PA-binding proteins on plasma membranes obtained from human liver and to determine whether such membranes would be a suitable starting material for the purification of such proteins.
The results show that plasma membranes prepared from human liver possess specific high-affinity binding sites for t-PA, having a dissociation constant of 3.4 + 0.8 nm. The t-PA-binding protein was present only in trace amounts (approx. 0.01 % of total membrane protein), whereas low-affinity binding sites were in excess (1 % of total protein). Binding appears to be specific for t-PA because it was not accompanied by the formation of t-PA-PAI-I complexes or inhibited by an excess of u-PA. In contrast, t-PA bound to HepG2 cell-derived membranes was fully complexed to PAI-I and binding was inhibited by active u-PA, but not by pro-u-PA. These results suggest that PAI-l does not mediate the binding of t-PA to the liver membranes, but confirms the role of PAI-l in binding to HepG2 cells (Owensby et al., 1989; Morton et al., 1990) . These characteristics of t-PA binding to human liver membranes are similar to those observed for the binding of t-PA to rat hepatocytes (Krause et al., 1990) and rat Novikoff hepatoma cells (Nguyen et al., 1992) , and is distinct from the PAI-l-dependent binding of t-PA to HepG2 cells (Owensby et al., 1989; Morton et al., 1990) .
The observation that t-PA binding to liver membranes was not affected by the presence of mannose suggests that, under these conditions, most t-PA binding is not via the mannose receptor. Gel filtration analysis showed that a protein with a high affinity for t-PA elutes at an apparent molecular mass of approx. 40 kDa.
Using mAbs specific for the different domains of t-PA, we tried to identify the domain(s) mediating the binding of t-PA to liver membranes. MAbs specific for the EGF domain and the kringle 2 domain blocked the binding of t-PA to the liver membranes, whereas a mAb specific for the kringle 1 domain partially blocked t-PA binding, and mAbs specific for the proteinase domain or the finger domain of t-PA had no effect on binding. Some of the antibodies directed against the growth factor and the kringle 2 domains were shown to block the degradation of t-PA by rat Novikoff hepatoma cells (a model system for t-PA catabolism by hepatocyte-like cells; Nguyen et al., 1992) whereas u-PA had no effect. These results suggest that the growth factor and kringle 2 domains of t-PA are involved in binding to the clearance receptor on these hepatocyte-like cells, whereas the proteinase domain seems not to be involved. We cannot exclude the possibility, however, that binding of an mAb to the kringle 2 or growth factor domain disturbs the spatial structure of t-PA and thus interferes with the binding of t-PA to its receptor. The observation that most of the t-PA domain deletion mutants have a prolonged clearance in vivo (Krause, 1988) may support either of the possibilities.
Pro-u-PA also bound to human liver membranes. Binding of pro-u-PA was inhibited by pro-u-PA, u-PA and the N-terminal fragment of u-PA, but only to a limited extent by the lowmolecular mass form of u-PA, which lacks the growth factor and kringle domains. These results suggest that the domain of u-PA involved in binding is either the kringle domain or the growth factor domain. Furthermore, these results, in combination with the inability of t-PA to block u-PA binding, make it unlikely that PAI-I is involved in the binding of u-PA to the liver membranes.
In conclusion, isolated human liver membranes contain highaffinity binding sites for t-PA that are distinct from the u-PAbinding sites. The characteristics of these t-PA-binding sites are compatible with those of the PAI-1-independent t-PA clearance receptor.
